BR112012016305A2 - "plasmídeos e métodos para exibição de peptídeo e seleção de afinidade em partículas semelhantes a vírus de bacteriófagos de rna" - Google Patents

"plasmídeos e métodos para exibição de peptídeo e seleção de afinidade em partículas semelhantes a vírus de bacteriófagos de rna"

Info

Publication number
BR112012016305A2
BR112012016305A2 BR112012016305A BR112012016305A BR112012016305A2 BR 112012016305 A2 BR112012016305 A2 BR 112012016305A2 BR 112012016305 A BR112012016305 A BR 112012016305A BR 112012016305 A BR112012016305 A BR 112012016305A BR 112012016305 A2 BR112012016305 A2 BR 112012016305A2
Authority
BR
Brazil
Prior art keywords
virus
particles
vlps
valence
methods
Prior art date
Application number
BR112012016305A
Other languages
English (en)
Inventor
Chackerian Bryce
S Peabody David
Original Assignee
Stc Unm
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Stc Unm filed Critical Stc Unm
Publication of BR112012016305A2 publication Critical patent/BR112012016305A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • C—CHEMISTRY; METALLURGY
    • C40—COMBINATORIAL TECHNOLOGY
    • C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B40/00—Libraries per se, e.g. arrays, mixtures
    • C40B40/02—Libraries contained in or displayed by microorganisms, e.g. bacteria or animal cells; Libraries contained in or displayed by vectors, e.g. plasmids; Libraries containing only microorganisms or vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/07—Bacillus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1037—Screening libraries presented on the surface of microorganisms, e.g. phage display, E. coli display
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2795/00—Bacteriophages
    • C12N2795/00011—Details
    • C12N2795/16011—Details ssRNA Bacteriophages negative-sense
    • C12N2795/16021—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2795/00—Bacteriophages
    • C12N2795/00011—Details
    • C12N2795/16011—Details ssRNA Bacteriophages negative-sense
    • C12N2795/16022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2795/00—Bacteriophages
    • C12N2795/00011—Details
    • C12N2795/16011—Details ssRNA Bacteriophages negative-sense
    • C12N2795/16023—Virus like particles [VLP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2795/00—Bacteriophages
    • C12N2795/00011—Details
    • C12N2795/16011—Details ssRNA Bacteriophages negative-sense
    • C12N2795/16041—Use of virus, viral particle or viral elements as a vector
    • C12N2795/16042—Use of virus, viral particle or viral elements as a vector virus or viral particle as vehicle, e.g. encapsulating small organic molecule
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2795/00—Bacteriophages
    • C12N2795/00011—Details
    • C12N2795/18011—Details ssRNA Bacteriophages positive-sense
    • C12N2795/18023—Virus like particles [VLP]
    • C—CHEMISTRY; METALLURGY
    • C40—COMBINATORIAL TECHNOLOGY
    • C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B40/00—Libraries per se, e.g. arrays, mixtures
    • C40B40/04—Libraries containing only organic compounds
    • C40B40/06—Libraries containing nucleotides or polynucleotides, or derivatives thereof
    • C40B40/08—Libraries containing RNA or DNA which encodes proteins, e.g. gene libraries

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Mycology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Plant Pathology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

patente de invenção: "plasmídeos e métodos para exibição de peptídeo e seleção de afinidade em partículas semelhantes a vírus de bacteriófagos de rna". a presente invenção refere-se a um sistema e a métodos para controlar a valência de exibição de pepídeos em particulas semelhantes a vírus (vlps), especialmente incluindo vlps ms2. neste método, grandes quantidades de proteínas revestidas do tipo selvagem e baixas quantidades de proteínas revestidas de dímero de cadeia única podem ser produzidas de um único rna. a valência é controlada na produção de imunògeno (vacina), proporcionando um sistema que permite a produção de grandes quantidades de proteínas revestidas do tipo selvagem e baixas quantidades de proteínas revestidas de dímero de cadeia única podem ser produzidas de um único rna, permitindo o ajuste fácil de niveis de valência de exibição em vlps, especialmente vlps ms2 por uma ampla gama de um, em média, até tantoquanto 90 por partícula. isto facilita a produção de imunógenos e vacinas, incluindo vlps exibindo valência baixa. as construções de ácido nucleico úteis na expressão de partículas semelhantes a vírus são apresentadas, compreendendo um polipeptídeo revestido de ms2 modoficado pela inserção de um peptídeo heterólogo, em que o peptídeo heterólogo é exibido sobre a partícula semelante a vírus e encapsula o ms2 de nirna. as construções de ácido nucleico são tmbém apresentadas, as quais são úteis na expressão de partículas semelhantes a vírus compreendendo um polipepeptídeo revestido de pp7 modificado pela inserção de um peptídeo heterólogo, em que o peptídeo heterólogo é exibido sobre a particula semelhante a vírus e encapsula o pp7 de mrna.
BR112012016305A 2009-12-31 2010-12-31 "plasmídeos e métodos para exibição de peptídeo e seleção de afinidade em partículas semelhantes a vírus de bacteriófagos de rna" BR112012016305A2 (pt)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US33512209P 2009-12-31 2009-12-31
US33512109P 2009-12-31 2009-12-31
US33512009P 2009-12-31 2009-12-31
PCT/US2010/062638 WO2011082381A2 (en) 2009-12-31 2010-12-31 Plasmids and methods for peptide display and affinity-selection on virus-like particles of rna bacteriophages

Publications (1)

Publication Number Publication Date
BR112012016305A2 true BR112012016305A2 (pt) 2017-05-02

Family

ID=44227171

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112012016305A BR112012016305A2 (pt) 2009-12-31 2010-12-31 "plasmídeos e métodos para exibição de peptídeo e seleção de afinidade em partículas semelhantes a vírus de bacteriófagos de rna"

Country Status (9)

Country Link
US (3) US9365831B2 (pt)
EP (1) EP2519627B1 (pt)
JP (1) JP2013516181A (pt)
CN (1) CN102858960B (pt)
BR (1) BR112012016305A2 (pt)
CA (1) CA2785992C (pt)
ES (1) ES2578979T3 (pt)
HK (1) HK1174662A1 (pt)
WO (1) WO2011082381A2 (pt)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013063366A2 (en) * 2011-10-27 2013-05-02 Stc.Unm Methods for screening viral like particles and identifying neutralizing epitopes and related vaccines, constructs, and libraries
US9549976B1 (en) 2012-11-16 2017-01-24 Stc.Unm Affinity selection of Nipah and Hendra virus-related vaccine candidates from a complex random peptide library displayed on bacteriophage virus-like particles
BR112016006344A2 (pt) * 2013-09-12 2018-01-09 Leidos Inc vacina contra a malária, composição e métodos
US10768181B2 (en) 2013-12-17 2020-09-08 The Brigham And Women's Hospital, Inc. Detection of an antibody against a pathogen
CN103923887A (zh) * 2014-04-16 2014-07-16 辽宁医学院 含戊型肝炎病毒rna片段的假病毒颗粒及其制备方法
CN105755026B (zh) * 2014-12-18 2020-06-23 天演药业（苏州）有限公司 过滤载体及其应用
DE16703049T1 (de) 2015-01-15 2018-07-12 University Of Copenhagen Virusähnliche partikel mit effizienter epitopanzeige
WO2017071713A1 (en) 2015-10-30 2017-05-04 University Of Copenhagen Virus like particle with efficient epitope display
EP3408284A4 (en) * 2016-01-28 2019-08-14 The Brigham and Women's Hospital, Inc. DETECTION OF ANTIBODY DIRECTED AGAINST A PATHOGENIC AGENT
CN106806890A (zh) * 2016-12-28 2017-06-09 中国医学科学院医学生物学研究所 重组人vegf多肽肿瘤疫苗
EP3595710A4 (en) * 2017-03-13 2021-01-13 Duke University ANTIGENT DISPLAY SYSTEM AND METHOD FOR CHARACTERIZING ANTIBODY REACTIONS
WO2022169665A1 (en) * 2021-02-05 2022-08-11 Unm Rainforest Innovations Bacteriophage virus-like particle vaccines against flavivirus non-structural protein 1
EP4355882A2 (en) 2021-06-15 2024-04-24 Modernatx, Inc. Engineered polynucleotides for cell-type or microenvironment-specific expression
CN114085930B (zh) * 2022-01-21 2022-04-12 广州国家实验室 用于检测SARS-CoV-2核酸的SERS检测试剂盒及方法
WO2024026254A1 (en) 2022-07-26 2024-02-01 Modernatx, Inc. Engineered polynucleotides for temporal control of expression

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60108102T2 (de) 2000-05-03 2005-12-15 EMD Biosciences, Inc., San Diego E. coli extrakt zur synthese von proteinen
JP2004089069A (ja) * 2002-08-30 2004-03-25 Mitsubishi Chemicals Corp 多コピー提示ファージの製造方法
JP4283563B2 (ja) 2003-03-04 2009-06-24 積水化学工業株式会社 木質マットの搬送装置
WO2008024427A2 (en) * 2006-08-23 2008-02-28 Science & Technology Corporation @ Unm A virus-like platform for rapid vaccine discovery

Also Published As

Publication number Publication date
US20120295813A1 (en) 2012-11-22
HK1174662A1 (en) 2013-06-14
CN102858960B (zh) 2014-11-26
US9365831B2 (en) 2016-06-14
WO2011082381A2 (en) 2011-07-07
CA2785992C (en) 2019-10-08
EP2519627A4 (en) 2013-12-18
WO2011082381A3 (en) 2011-12-22
US20210338793A1 (en) 2021-11-04
CA2785992A1 (en) 2011-07-07
US20160354459A1 (en) 2016-12-08
JP2013516181A (ja) 2013-05-13
EP2519627A2 (en) 2012-11-07
CN102858960A (zh) 2013-01-02
ES2578979T3 (es) 2016-08-03
EP2519627B1 (en) 2016-03-30

Similar Documents

Publication Publication Date Title
BR112012016305A2 (pt) "plasmídeos e métodos para exibição de peptídeo e seleção de afinidade em partículas semelhantes a vírus de bacteriófagos de rna"
AR124871A2 (es) Métodos de fabricación para el control del contenido de lisina c-terminal, galactosa y ácido siálico en proteínas recombinantes
MX2017010117A (es) Casetes optimizados de expresión del gen humano del factor viii de coagulación y su uso.
MX358762B (es) Procesos que utilizan vlps con cápsides resistentes a hidrolasas.
CA3062698A1 (en) Nucleic acid molecules encoding an engineered antigen receptor and an inhibitory nucleic acid molecule and methods of use thereof
WO2013003353A3 (en) Plasmids and methods for peptide display and affinity-selection on virus-like particles of rna bacteriophages
MX357803B (es) Moléculas de ácido nucleico artificiales.
BR112015022978A2 (pt) agente de ligação biespecífico, seu método de produção composição farmacêutica, proteína de fusão, uso, sequência de ácido nucleico, vetor, célula hospedeira, método de matar células tumorais e de inibir o crescimento tumoral
MX2013008836A (es) Moleculas de acido nucleico que codifican novedosos antigenos de herpes, vacunas que las comprenden y metodos para su uso.
CA2851316C (en) Genes and proteins for alkanoyl-coa synthesis
MX2012008651A (es) Moleculas de acido nucleico de influenza y vacunas elaboradas a partir de las mismas.
MX2019006633A (es) Formulaciones de anticuerpo.
BR112014019901A8 (pt) Proteínas de fator viii recombinante
MX2013003681A (es) Ácidos nucleicos manipulados y métodos de uso de los mismos.
MY161965A (en) New influenza virus immunizing epitope
WO2012083445A8 (en) Virus like particle production in plants
EP3210622A3 (en) Recombinant avian paramyxovirus vaccine and method for making and using thereof
EP4095152A3 (en) Engineered ribosomal promoters for protein production in microorganisms
MX349657B (es) Composiciones de vacuna de matriz de proteína que incluyen policationes.
MX355890B (es) Estrategia de múltiples copias para producción de alto título y alta pureza de proteínas de multi-subunidades tales como anticuerpos en microbios transformados tal como pichia pastoris.
PH12019500578A1 (en) New promoters
MX2022010985A (es) Expresión de proteínas sars-cov, constructos de ácido nucleico, proteínas tipo virus (vlp) y métodos relevantes a los mismos.
EA201991702A1 (ru) Самосборные белковые наночастицы, инкапсулирующие иммуностимулирующие нуклеиновые кислоты
PH12020500526A1 (en) Paramyxoviridae expression system
MX2009011851A (es) Plasmidos de dna que tienen expresion y estabilidad mejoradas.

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements
B350 Update of information on the portal [chapter 15.35 patent gazette]